On Apr. 16, 2020, the International Vaccine Institute (IVI) announced that the Coalition for Epidemic Preparedness Innovations (CEPI) had granted $6.9 million funding to INOVIO to work with IVI and the Korea National Institute of Health (KNIH) for a Phase 1/2 clinical trial of INOVIO’s COVID-19 vaccine candidate (INO-4800) in South Korea.

IVI conducted the trial in parallel to INOVIO’s Phase 1 INO-4800 study underway in the U.S. since April 6, 2020 with 40 healthy adults receiving the vaccine candidate and eventually expanding to older adults.